Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis

Antimicrob Agents Chemother. 2001 Feb;45(2):621-3. doi: 10.1128/AAC.45.2.621-623.2001.

Abstract

We compared the activities of linezolid (25 mg/kg of body weight, administered intraperitoneally every 8 h) and of vancomycin (25 mg/kg of body weight, administered intraperitoneally every 8 h) in a rat model of vanA vancomycin-resistant Enterococcus faecium experimental endocarditis. Results were expressed as median log(10) CFU per gram of vegetation after 3 days of treatment. The median log(10) CFU per gram of vegetation was 10.1 among 7 untreated control animals, 10.2 among 9 vancomycin-treated animals, and 7.9 among 10 linezolid-treated animals. Linezolid treatment was more active (P < 0.05) than vancomycin treatment or no treatment.

MeSH terms

  • Acetamides / therapeutic use*
  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Bacterial Proteins / genetics
  • Carbon-Oxygen Ligases / genetics
  • Drug Resistance, Microbial
  • Endocarditis, Bacterial / drug therapy*
  • Endocarditis, Bacterial / microbiology
  • Enterococcus faecium / drug effects*
  • Enterococcus faecium / genetics
  • Genotype
  • Linezolid
  • Male
  • Oxazolidinones / therapeutic use*
  • Rats
  • Rats, Wistar
  • Vancomycin Resistance / genetics*

Substances

  • Acetamides
  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Oxazolidinones
  • VanA ligase, Bacteria
  • Carbon-Oxygen Ligases
  • Linezolid